Denali therapeutics announces closing of a $316 million public offering, including full exercise of underwriters' option to purchase additional shares

South san francisco, calif., oct. 24, 2022 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli) today announced the closing of its upsized underwritten public offering of 11,933,962 shares of its common stock at a price to the public of $26.50 per share, which includes the exercise in full by the underwriters of their option to purchase additional shares. the total gross proceeds from the offering, before deducting underwriters' discounts and commissions and estimated offering expenses, are approximately $316 million.
DNLI Ratings Summary
DNLI Quant Ranking